# Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

> **NCT05277480** · PHASE2 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 81 (actual)

## Conditions studied

- Effect of Drug
- Drug
- Toxicity

## Interventions

- **DRUG:** Apatinib+IE
- **DRUG:** IE

## Key facts

- **NCT ID:** NCT05277480
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-11-26
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277480, "Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05277480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*